hydroxychloroquine has been researched along with Chilblains in 13 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Chilblains: Recurrent localized itching, swelling and painful erythema on the fingers, toes or ears, produced by exposure to cold.
| Excerpt | Relevance | Reference |
|---|---|---|
| " She did not have persistent good improvement despite treatment with 1 mg/kg oral prednisolone, along with successive trials with many steroid-sparing adjuvants in adequate dosage and duration, including hydroxychloroquine, methotrexate and cyclosporine, in the following 6 months." | 1.72 | B cell depletion therapy using rituximab to induce long-term remission of recalcitrant skin lesions of subacute cutaneous lupus erythematosus. ( Arava, S; Baskaran, N; Gupta, S; Mehta, N, 2022) |
| "Lupus pernio (LP) occurs in the form of smooth, bright nodules and plaques on the nose, ear, lips, and cheeks." | 1.56 | A case of chronic sarcoidosis presenting with lupus pernio. ( Duru Çetinkaya, P, 2020) |
| "Hydroxychloroquine is a relatively safe, well tolerated alternative therapy for the treatment of perniosis and should be considered as part of the initial management." | 1.36 | Successful treatment of perniosis with hydroxychloroquine. ( English, JC; Perez, OA; Yang, X, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 3 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Mehta, N | 1 |
| Baskaran, N | 1 |
| Arava, S | 1 |
| Gupta, S | 1 |
| Manor, U | 1 |
| Dankovich, N | 1 |
| Boleslavsky, D | 1 |
| Kivity, S | 1 |
| Stienlauf, S | 1 |
| Duru Çetinkaya, P | 1 |
| Ishiguro, Y | 1 |
| Muro, Y | 1 |
| Murase, C | 1 |
| Takeichi, T | 1 |
| Kono, M | 1 |
| Adachi, R | 1 |
| Takahashi, K | 1 |
| Akiyama, M | 1 |
| Horino, T | 1 |
| Ichii, O | 1 |
| Terada, Y | 1 |
| Günther, C | 1 |
| Hillebrand, M | 1 |
| Brunk, J | 1 |
| Lee-Kirsch, MA | 1 |
| Patel, S | 1 |
| Hardo, F | 1 |
| Mireku, KA | 1 |
| Glover, MH | 1 |
| Davis, L | 1 |
| Yang, X | 1 |
| Perez, OA | 1 |
| English, JC | 1 |
| Francès, C | 2 |
| Cosnes, A | 1 |
| Duhaut, P | 1 |
| Zahr, N | 1 |
| Soutou, B | 1 |
| Ingen-Housz-Oro, S | 1 |
| Bessis, D | 1 |
| Chevrant-Breton, J | 1 |
| Cordel, N | 1 |
| Lipsker, D | 1 |
| Costedoat-Chalumeau, N | 1 |
| BETTLEY, FR | 1 |
| Bouaziz, JD | 1 |
| Barete, S | 1 |
| Le Pelletier, F | 1 |
| Amoura, Z | 1 |
| Piette, JC | 1 |
| Pock, L | 1 |
| Petrovská, P | 1 |
| Becvár, R | 1 |
| Mandys, V | 1 |
| Hercogová, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Oral Psoriasis Treatment Adherence and Intervention Study[NCT02850900] | 29 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
13 other studies available for hydroxychloroquine and Chilblains
| Article | Year |
|---|---|
B cell depletion therapy using rituximab to induce long-term remission of recalcitrant skin lesions of subacute cutaneous lupus erythematosus.
Topics: Chilblains; Cyclosporine; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Cutaneous; Rituxi | 2022 |
Chilblains in a Patient with Systemic Lupus Erythematosus: Another Manifestation of the Great Masquerader.
Topics: Antirheumatic Agents; Autoantibodies; Biopsy; Chilblains; Glucocorticoids; Humans; Hydroxychloroquin | 2019 |
A case of chronic sarcoidosis presenting with lupus pernio.
Topics: Antirheumatic Agents; Biopsy; Chilblains; Diagnosis, Differential; Female; Humans; Hydroxychloroquin | 2020 |
Drug-induced acute eosinophilic pneumonia due to hydroxychloroquine in a chilblain lupus patient.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Betamethasone; Chilblains; Drug Therapy, Comb | 2019 |
Hydroxychloroquine-Associated Hyperpigmentation in Chilblain Lupus Erythematosus.
Topics: Chilblains; Humans; Hydroxychloroquine; Hyperpigmentation; Lupus Erythematosus, Cutaneous; Lupus Ery | 2020 |
Systemic involvement in TREX1-associated familial chilblain lupus.
Topics: Chilblains; Exodeoxyribonucleases; Follow-Up Studies; Genetic Predisposition to Disease; Heterozygot | 2013 |
Chilblain lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Chilblains; Diagnosis, Differential; Female; Humans; Hydroxychloroquine | 2013 |
Tender macules and papules on the toes.
Topics: Administration, Topical; Chilblains; Clobetasol; Dermatologic Agents; Diagnosis, Differential; Femal | 2014 |
Successful treatment of perniosis with hydroxychloroquine.
Topics: Adolescent; Adult; Chilblains; Female; Humans; Hydroxychloroquine; Retrospective Studies | 2010 |
Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Chilblains; Child; Female; France; Humans | 2012 |
Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Chilblains; Child; Female; France; Humans | 2012 |
Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Chilblains; Child; Female; France; Humans | 2012 |
Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Chilblains; Child; Female; France; Humans | 2012 |
CHILBLAIN LUPUS ERYTHEMATOSUS.
Topics: Chilblains; Chloroquine; Fluocinolone Acetonide; Frostbite; Humans; Hydroxychloroquine; Hypothyroidi | 1964 |
Cutaneous lesions of the digits in systemic lupus erythematosus: 50 cases.
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Chilblains; Child; Cohort St | 2007 |
Verrucous form of chilblain lupus erythematosus.
Topics: Biopsy, Needle; Chilblains; Female; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Humans; Hyd | 2001 |